Last reviewed · How we verify
IV Corticosteroid
IV corticosteroids suppress immune and inflammatory responses by inhibiting cytokine production and reducing immune cell activation.
IV corticosteroids suppress immune and inflammatory responses by inhibiting cytokine production and reducing immune cell activation. Used for Acute severe inflammation or inflammatory conditions, Autoimmune disorders, Severe allergic reactions.
At a glance
| Generic name | IV Corticosteroid |
|---|---|
| Also known as | Prednisone |
| Sponsor | Connecticut Children's Medical Center |
| Drug class | Corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Critical Care |
| Phase | FDA-approved |
Mechanism of action
Corticosteroids bind to glucocorticoid receptors in the cytoplasm and translocate to the nucleus, where they modulate gene transcription to decrease production of pro-inflammatory cytokines (IL-1, IL-6, TNF-α) and reduce immune cell proliferation and migration. This broad immunosuppressive effect reduces inflammation across multiple organ systems and is used acutely in severe inflammatory or autoimmune conditions.
Approved indications
- Acute severe inflammation or inflammatory conditions
- Autoimmune disorders
- Severe allergic reactions
- Cerebral edema
- Status asthmaticus
Common side effects
- Hyperglycemia
- Hypertension
- Insomnia
- Mood changes / agitation
- Immunosuppression / increased infection risk
- Hypokalemia
Key clinical trials
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
- Gene Replacement Therapy for Treatment of Paediatric Patients With CTNNB1 Neurodevelopmental Syndrome (PHASE1, PHASE2)
- Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids (PHASE1, PHASE2)
- A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma (PHASE3)
- A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01) (PHASE2)
- MAGIC Ruxolitinib for aGVHD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IV Corticosteroid CI brief — competitive landscape report
- IV Corticosteroid updates RSS · CI watch RSS
- Connecticut Children's Medical Center portfolio CI